Eric Dube Sells 51,865 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric Dube sold 51,865 shares of the business’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $30.10, for a total transaction of $1,561,136.50. Following the completion of the transaction, the chief executive officer owned 419,173 shares of the company’s stock, valued at approximately $12,617,107.30. This represents a 11.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Travere Therapeutics Price Performance

Shares of Travere Therapeutics stock opened at $30.28 on Thursday. Travere Therapeutics, Inc. has a twelve month low of $12.91 and a twelve month high of $42.13. The firm has a market cap of $2.71 billion, a PE ratio of -28.57, a P/E/G ratio of 0.99 and a beta of 0.85. The company has a quick ratio of 2.71, a current ratio of 2.75 and a debt-to-equity ratio of 4.23. The business has a 50-day moving average price of $34.35 and a 200 day moving average price of $27.24.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.31) by $0.59. Travere Therapeutics had a negative net margin of 20.32% and a negative return on equity of 178.68%. The company had revenue of $164.86 million during the quarter, compared to analyst estimates of $106.09 million. During the same quarter in the previous year, the firm earned ($0.70) EPS. The firm’s revenue was up 162.1% compared to the same quarter last year. Sell-side analysts predict that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TVTX has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $47.00 price objective on shares of Travere Therapeutics in a report on Friday, November 28th. Zacks Research downgraded shares of Travere Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 12th. TD Cowen restated a “buy” rating on shares of Travere Therapeutics in a report on Friday, October 31st. Finally, Guggenheim reissued a “buy” rating and issued a $49.00 price objective on shares of Travere Therapeutics in a research report on Wednesday, January 14th. Twelve equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.86.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of TVTX. Raymond James Financial Inc. acquired a new stake in shares of Travere Therapeutics during the second quarter worth $33,000. First Horizon Corp purchased a new position in Travere Therapeutics in the 3rd quarter valued at approximately $36,000. Headlands Technologies LLC purchased a new position in shares of Travere Therapeutics in the second quarter valued at $73,000. Atria Investments Inc purchased a new position in Travere Therapeutics during the 2nd quarter valued at about $154,000. Finally, Gallagher Fiduciary Advisors LLC purchased a new position in shares of Travere Therapeutics during the 2nd quarter worth approximately $155,000.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.